Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

People with lupus are at an increased risk of depression. Lupus is a chronic condition with recurring symptoms that can ...

Your gut microbiome can trigger an immune response, leading to chronic systemic inflammation and lupus. Here are some tips to ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

known as Atypical B cells (ABCs), to fight infectious diseases such as malaria. The scientists say ABCs ... Discovery May Enable an Effective Long-Term Lupus Treatment Feb. 6, 2024 — Researchers ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without customization. However, some NK companies, such as Fate Therapeutics and Cytovia ...

The study examines 79 lupus patients and 64 healthy individuals, focusing on B cells, the antibody-producing white blood cells vital for immune defense. In healthy individuals, mRNA COVID-19 ...

The researchers believe their findings will have broad application to autoimmune diseases with defective B cell components beyond just lupus, while providing more insights into personalized ...